Biophytis, US09076G1040

Biophytis, US09076G1040

07.09.2022 - 08:03:09

Biophytis announces very promising top line results of its phase 2-3 COVA clinical study in COVID-19-related respiratory failure

Biophytis Contact for Investor Relations

Philippe Rousseau CFO

Investors@biophytis.com

?

Media Contacts

Antoine Denry?:?antoine.denry@taddeo.fr? +33 6 18 07 83 27Agathe Boggio?:?agathe.boggio@taddeo.fr? +33 7 62 77 69 42

Dissemination of a Financial Wire News, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.

Language: English Issuer: Biophytis 14 avenue de l?Op?ra 75001 Paris

France Internet: https://www.biophytis.com ISIN: US09076G1040, FR0012816825 EQS News ID: 1436909 ? End of Announcement - EQS News Service

1436909??07-Sep-2022?CET/CEST

@ dgap.de